C. Cebotaru

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 162 citations · Full text

Urology, Oncology, Metastatic Urothelial Carcinoma +7

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

John D. Hainsworth, C. Cebotaru, Vladimir Kanarev et al. · Journal of Thoracic Oncology · 2010 · 159 citations · Full text

Phase Ii, Advanced Lung Disease, Medicine +10

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Primary breast lymphoma: a report of 20 cases

Vincent Ribrag, Frédéric Bibeau, Amr El Weshi et al. · British Journal of Haematology · 2001 · 100 citations · Full text

Neuro-oncology, Lymphoid Neoplasia, Breast Oncology +13

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Joachim von Pawel, Jimmie H. Harvey, David R. Spigel et al. · Clinical Lung Cancer · 2014 · 97 citations

Phase Ii Trial, Medicine, Immunology +7